Celsion Corporation ($CLSN) reported receiving two new patents for ThermoDox formulation. The company said that one patent has been granted by the United States Patent and Trademark Office, while the other comes from Korea. These patents will help boosting the global coverage of ThermoDox, which is currently in Phase III development for the treatment of primary liver cancer, also known as hepatocellular carcinoma.
The company also announced continued data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer.
The company stated that in the first twelve patients dosed in the OVATION Study, GEN-1 plus standard chemotherapy produced impressive results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer.
Celsion stock has performed very well this year so far. Its Year to Date gain stands at over 35%, which has helped recoup some of the losses it incurred in 2016. The current market price for the stock is more than 50% down from its 52 weeks high, providing good entry point for building mid term or long term position.